Ryvu Therapeutics S.A. (RVU.WA)
PLN 36.5
(-3.95%)
PLN 36.5
(-3.95%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 365 Thousand PLN | -57.8% |
| 2022 | 865 Thousand PLN | -62.69% |
| 2021 | 2.31 Million PLN | -46.41% |
| 2020 | 4.32 Million PLN | 83.18% |
| 2019 | 2.36 Million PLN | -76.47% |
| 2018 | 10.03 Million PLN | 62.67% |
| 2017 | 6.16 Million PLN | -21.1% |
| 2016 | 7.81 Million PLN | 2527.37% |
| 2015 | 297.61 Thousand PLN | 68.25% |
| 2014 | 176.89 Thousand PLN | 61.76% |
| 2013 | 109.35 Thousand PLN | 0.0% |
| 2012 | - PLN | 0.0% |
| 2011 | - PLN | 0.0% |
| 2010 | - PLN | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 79.38 Million PLN | 0.0% |
| 2024 Q2 | 51.55 Million PLN | -35.37% |
| 2023 Q2 | 475 Thousand PLN | -31.26% |
| 2023 Q1 | 691 Thousand PLN | -20.12% |
| 2023 FY | 365 Thousand PLN | -57.8% |
| 2023 Q4 | 365 Thousand PLN | -14.12% |
| 2023 Q3 | 425 Thousand PLN | -10.53% |
| 2022 Q3 | 1.27 Million PLN | -22.98% |
| 2022 Q1 | 1.96 Million PLN | -15.46% |
| 2022 Q2 | 1.65 Million PLN | -15.42% |
| 2022 FY | 865 Thousand PLN | -62.69% |
| 2022 Q4 | 865 Thousand PLN | -32.26% |
| 2021 Q2 | 3.45 Million PLN | -8.83% |
| 2021 Q1 | 3.78 Million PLN | -12.54% |
| 2021 Q3 | 2.98 Million PLN | -13.59% |
| 2021 Q4 | 2.31 Million PLN | -22.23% |
| 2021 FY | 2.31 Million PLN | -46.41% |
| 2020 Q4 | 4.32 Million PLN | -12.44% |
| 2020 Q1 | 8.87 Million PLN | 50.04% |
| 2020 FY | 4.32 Million PLN | 83.18% |
| 2020 Q2 | 5.85 Million PLN | -34.11% |
| 2020 Q3 | 4.94 Million PLN | -15.54% |
| 2019 Q2 | 2.76 Million PLN | -6.82% |
| 2019 Q4 | 5.91 Million PLN | -50.16% |
| 2019 Q1 | 2.96 Million PLN | -70.41% |
| 2019 FY | 2.36 Million PLN | -76.47% |
| 2019 Q3 | 11.87 Million PLN | 329.17% |
| 2018 Q4 | 10.03 Million PLN | 197.44% |
| 2018 FY | 10.03 Million PLN | 62.67% |
| 2018 Q2 | 3.57 Million PLN | -5.36% |
| 2018 Q1 | 3.77 Million PLN | -38.75% |
| 2018 Q3 | 3.37 Million PLN | -5.66% |
| 2017 Q3 | 4.18 Million PLN | -4.62% |
| 2017 Q4 | 6.16 Million PLN | 47.46% |
| 2017 FY | 6.16 Million PLN | -21.1% |
| 2017 Q2 | 4.38 Million PLN | -5.8% |
| 2017 Q1 | 4.65 Million PLN | -40.45% |
| 2016 Q1 | 1.13 Million PLN | 281.47% |
| 2016 FY | 7.81 Million PLN | 2527.37% |
| 2016 Q4 | 7.81 Million PLN | 208.27% |
| 2016 Q3 | 2.53 Million PLN | 70.04% |
| 2016 Q2 | 1.49 Million PLN | 31.39% |
| 2015 Q4 | 297.61 Thousand PLN | -18.68% |
| 2015 Q1 | 176.89 Thousand PLN | 0.0% |
| 2015 Q2 | 338.9 Thousand PLN | 91.59% |
| 2015 Q3 | 365.98 Thousand PLN | 7.99% |
| 2015 FY | 297.61 Thousand PLN | 68.25% |
| 2014 Q4 | 176.89 Thousand PLN | -64.85% |
| 2014 FY | 176.89 Thousand PLN | 61.76% |
| 2014 Q1 | 164.55 Thousand PLN | 50.47% |
| 2014 Q2 | 503.23 Thousand PLN | 205.82% |
| 2014 Q3 | 503.23 Thousand PLN | 0.0% |
| 2013 Q3 | - PLN | 0.0% |
| 2013 Q4 | 109.35 Thousand PLN | 0.0% |
| 2013 FY | 109.35 Thousand PLN | 0.0% |
| 2013 Q2 | - PLN | 0.0% |
| 2013 Q1 | - PLN | 0.0% |
| 2012 Q4 | - PLN | 0.0% |
| 2012 FY | - PLN | 0.0% |
| 2011 FY | - PLN | 0.0% |
| 2010 FY | - PLN | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Bioceltix S.A. | 76.33 Thousand PLN | -378.168% |
| BIOTON S.A. | 12.67 Million PLN | 97.121% |
| Captor Therapeutics Spolka Akcyjna | 1.24 Million PLN | 70.73% |
| Mabion S.A. | 2.94 Million PLN | 87.619% |
| Molecure S.A. | 4.97 Million PLN | 92.665% |
| NanoGroup S.A. | - PLN | -Infinity% |
| Pharmena S.A. | 114 Thousand PLN | -220.175% |
| Poltreg S.A. | 7.8 Million PLN | 95.321% |
| Pure Biologics Spólka Akcyjna | 12.85 Million PLN | 97.16% |
| Synthaverse S.A. | 61.2 Million PLN | 99.404% |
| Urteste S.A. | 312 Thousand PLN | -16.987% |